More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

Outlook Therapeutics believes this determination is inconsistent with the totality of evidence submitted in the BLA, including data from an adequate and well-controlled study and confirmatory evidence ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina ...

Brad Zukeran ’24 is pursuing a major in environmental science and minors in political science and history at Santa Clara University. Zukeran was a 2022-23 environmental ethics fellow at the Markkula ...